Notably, engineered anti-CD19 CAR T cells that secrete anti-programmed death-ligand 1 (PD-L1) scFv demonstrate superior proliferation and enhanced anti-tumor functionality in comparison to anti-CD19 CAR T cells [58]. The gene discussed is CD19; the disease is neoplasm.